Elevance Health/$ELV
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Elevance Health
Elevance Health remains one of the leading health insurers in the US, providing medical benefits to 46 million medical members as of June 2025. The company offers employer, individual, and government-sponsored coverage plans. Elevance differs from its peers in its unique position as the largest single provider of Blue Cross Blue Shield branded coverage, operating as the licensee for the Blue Cross Blue Shield Association in 14 states. Through acquisitions, such as the Amerigroup deal in 2012 and MMM in 2021, Elevance's reach expands beyond those states through government-sponsored programs, such as Medicaid and Medicare Advantage plans, too. It is also an emerging player in pharmacy benefit management and other healthcare services.
Ticker
$ELV
Sector
Primary listing
NYSE
Employees
104,200
Headquarters
Website
Elevance Health Metrics
BasicAdvanced
$71B
13.47
$23.39
0.61
$6.68
2.17%
Price and volume
Market cap
$71B
Beta
0.61
52-week high
$552.55
52-week low
$273.71
Average daily volume
2.3M
Dividend rate
$6.68
Financial strength
Current ratio
1.445
Quick ratio
1.321
Long term debt to equity
64.259
Total debt to equity
68.838
Dividend payout ratio (TTM)
28.40%
Interest coverage (TTM)
6.60%
Profitability
EBITDA (TTM)
9,487
Gross margin (TTM)
26.84%
Net profit margin (TTM)
2.83%
Operating margin (TTM)
4.62%
Effective tax rate (TTM)
24.32%
Revenue per employee (TTM)
$1,820,000
Management effectiveness
Return on assets (TTM)
4.65%
Return on equity (TTM)
12.42%
Valuation
Price to earnings (TTM)
13.465
Price to revenue (TTM)
0.38
Price to book
1.62
Price to tangible book (TTM)
18.32
Price to free cash flow (TTM)
13.476
Free cash flow yield (TTM)
7.42%
Free cash flow per share (TTM)
23.367
Dividend yield (TTM)
2.12%
Forward dividend yield
2.17%
Growth
Revenue change (TTM)
10.21%
Earnings per share change (TTM)
-17.86%
3-year revenue growth (CAGR)
8.27%
10-year revenue growth (CAGR)
9.47%
3-year earnings per share growth (CAGR)
-1.94%
10-year earnings per share growth (CAGR)
8.62%
3-year dividend per share growth (CAGR)
11.49%
10-year dividend per share growth (CAGR)
12.14%
What the Analysts think about Elevance Health
Analyst ratings (Buy, Hold, Sell) for Elevance Health stock.
Bulls say / Bears say
Elevance reported Q2 2025 operating revenue of $49.4 billion, a rise of 14.3% year-over-year and above analysts’ expectations of $48.23 billion, driven by higher premium yields, strategic acquisitions, and growth in Medicare Advantage membership (Reuters )
In Q1 2025, Elevance Health exceeded profit estimates with adjusted EPS of $11.97 compared to the $11.38 consensus and posted a medical loss ratio of 86.4%, below the expected 86.8%, signaling effective cost control in its Medicare Advantage segment (Reuters )
Following its Q1 results, Elevance reaffirmed its full-year 2025 profit target of $34.15–$34.85 per share, demonstrating management’s confidence in earnings strength despite sector-wide cost challenges (Reuters )
On July 17, 2025, Elevance lowered its full-year 2025 adjusted EPS guidance to around $30.00, down from its previous range of $34.15–$34.85 per share, indicating short-term profit challenges due to higher medical costs in ACA and Medicaid segments (Reuters )
Elevance’s medical loss ratio rose to 88.9% in Q2 2025, up 260 basis points year-over-year, highlighting rising cost pressures in Medicaid and ACA plans that are squeezing margins (Reuters )
Elevance shares dropped 8.1% in premarket trading after its Q2 earnings report and the cut to its profit outlook, reflecting market concerns about its ability to control increasing medical costs (Reuters )
Data summarised monthly by Lightyear AI. Last updated on 7 Sept 2025.
Elevance Health Financial Performance
Revenues and expenses
Elevance Health Earnings Performance
Company profitability
Elevance Health News
AllArticlesVideos
AM Best Assigns Issue Credit Ratings to Elevance Health, Inc. New Senior Unsecured Notes
Business Wire3 days ago
Elevance Health loses bid to challenge US Medicare star ratings
Reuters4 weeks ago
Elevance Health Board Welcomes Steve Collis as New Director, Reflecting Ongoing Commitment to Governance Excellence
Business Wire2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
Sept25
Elevance Health
DividendPayment
$1.71Per share
FAQs
What’s the current market cap for Elevance Health stock?
Elevance Health (ELV) has a market cap of $71B as of September 14, 2025.
What is the P/E ratio for Elevance Health stock?
The price to earnings (P/E) ratio for Elevance Health (ELV) stock is 13.47 as of September 14, 2025.
Does Elevance Health stock pay dividends?
Yes, the Elevance Health (ELV) stock pays dividends to shareholders. As of September 14, 2025, the dividend rate is $6.68 and the yield is 2.17%. Elevance Health has a payout ratio of 28.4% on a trailing twelve-month basis.
When is the next Elevance Health dividend payment date?
The next Elevance Health (ELV) dividend payment is scheduled for September 25, 2025.
What is the beta indicator for Elevance Health?
Elevance Health (ELV) has a beta rating of 0.61. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.